Comment by
tylerreddick on Feb 17, 2024 12:55pm
Extrapolate that to 100,000 units/month, which should be easily attainable once word gets out. That is serious money.
Comment by
tylerreddick on Feb 17, 2024 1:03pm
December's number is $55 million of annualised revenue, or about 17 cents/share FD. Margins should be very good, one would think at least 35%, which would give us earnings of 6 cents/share. A biotech with growing earnings and more potential products could easliy demand a PE ratio of 30 (or more). Can anyone get their head around a $2 share price? That would get some attention.
Comment by
lscfa on Feb 17, 2024 5:51pm
Geraldine noted in interview that clinical trials of formulations containing the active ingredient are required even if clinical trials of active ingredient have been done. 2nd half of 2024 is target for formulation trials.
Comment by
LakeOromocto on Feb 17, 2024 8:34pm
You call them and offer to loan the funds. How many PP have you participated in? Don't bite the hand that keeps the lights on!
Comment by
sakinny3 on Feb 18, 2024 11:19am
So they are planning to sell this for 250$ a go? That's not exactly mass market price
Comment by
lscfa on Feb 18, 2024 1:36pm
$250 is likely the price for a regimen like other companies do. e.g. 21 day intensive treatment, 50ml stronger face cream, 50ml milder face cream.
Comment by
tylerreddick on Feb 18, 2024 3:36pm
It looks like that price is probably for the trays with a the 21 little tubes of treatment, thus the 21-day regimen https://twitter.com/SironaBiochem/status/1752228505402667105
Comment by
lscfa on Feb 18, 2024 3:58pm
So $250 is likely for the serum (21 days), stronger face cream (4 to 6 wks) and milder face cream (4 to 6 weeks). After that, repeat sales of the milder face cream to maintain => $70 every 4 to 6 weeks?
Comment by
sakinny3 on Feb 19, 2024 1:50am
Can you tell me where all this estimated revenue data is coming from? I can't find it on the company websites. Thanks
Comment by
biorun on Feb 19, 2024 3:06pm
Good table. I would think an analysis which shows a 10 year proforma, discounted in present value terms would give an interesting NPV per share number. Some numbers could be a 13x to 20x PE mumtiple, and 12% discount rate to reflect the corporate loan rate.
Comment by
gr0und1ng on Feb 19, 2024 4:43pm
Now halve the numbers or move the decimal point one place forward and we are in a real possibility. Not that anyone will be disappointed if the numbers are not reached ;-)
Comment by
sakinny3 on Feb 20, 2024 1:11am
Hi Iscfa, on your reorder data, have you compounded as people will continue to reorder? Data seems to just account for 1 reorder?
Comment by
tylerreddick on Feb 19, 2024 8:38am
" Total margin is 90 percent. " Well, you just destroyed the little credibility you had.
Comment by
lscfa on Feb 19, 2024 11:52am
90% margin is gross margin. Marketing costs will be a large expense impacting operating margin and net profit margin.
Comment by
tylerreddick on Feb 19, 2024 12:05pm
Thanks for confirming what I posted.
Comment by
forhandlaren on Feb 19, 2024 9:11am
@tylerrreddick I accidentally noticed your comment since I wasn't logged in. The 90 percent has been stated by management. For the record. I don't care about your perception of my posts, please feel free to ignore me. I'll log in now so I won't be able to respond you from now on.
Comment by
tylerreddick on Feb 19, 2024 9:54am
" I accidentally noticed your comment since I wasn't logged in " Even more credibility erased.
Comment by
sakinny3 on Feb 19, 2024 9:37am
Is it correct to say that the presentation all the forecast data is taken from has not formally been released by the company?
Comment by
lscfa on Feb 19, 2024 5:47pm
I can envision GPM being licensed to someone for sales in Asia, possibly after doing further studies on different skins types. The study done in Paris was on only 20 women. Were they all caucasians?